Research Analysts Offer Predictions for MDGL FY2028 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) - Analysts at B. Riley issued their FY2028 earnings per share (EPS) estimates for Madrigal Pharmaceuticals in a research note issued on Thursday, May 1st. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will earn $42.69 per share for the year. B. Riley currently has a "Buy" rating and a $460.00 target price on the stock. The consensus estimate for Madrigal Pharmaceuticals' current full-year earnings is ($23.47) per share.

A number of other research analysts have also weighed in on MDGL. Citigroup increased their price objective on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a "buy" rating in a report on Thursday, February 27th. HC Wainwright lifted their price objective on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Canaccord Genuity Group upped their price target on shares of Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the company a "buy" rating in a report on Friday, May 2nd. StockNews.com raised shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday. Finally, UBS Group increased their price target on shares of Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $416.33.

Madrigal Pharmaceuticals Stock Performance

Shares of NASDAQ MDGL traded up $3.70 during mid-day trading on Monday, hitting $298.83. The stock had a trading volume of 359,721 shares, compared to its average volume of 386,986. The company has a 50 day moving average of $323.84 and a two-hundred day moving average of $315.87. Madrigal Pharmaceuticals has a twelve month low of $200.08 and a twelve month high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The firm has a market cap of $6.63 billion, a PE ratio of -11.92 and a beta of -0.91.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($3.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.62) by $0.30. The company had revenue of $137.25 million for the quarter, compared to analyst estimates of $112.79 million. During the same quarter last year, the company earned ($7.38) EPS.

Insider Buying and Selling

In other news, Director James M. Daly sold 15,470 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $347.45, for a total value of $5,375,051.50. Following the completion of the sale, the director now directly owns 1,912 shares in the company, valued at $664,324.40. This represents a 89.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Robert E. Waltermire sold 14,113 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $341.32, for a total transaction of $4,817,049.16. Following the transaction, the vice president now owns 3,728 shares in the company, valued at $1,272,440.96. The trade was a 79.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,810 shares of company stock worth $10,610,594 in the last 90 days. Insiders own 22.80% of the company's stock.

Institutional Trading of Madrigal Pharmaceuticals

A number of hedge funds have recently bought and sold shares of MDGL. VSM Wealth Advisory LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the first quarter valued at approximately $25,000. Farther Finance Advisors LLC raised its holdings in shares of Madrigal Pharmaceuticals by 825.0% during the 1st quarter. Farther Finance Advisors LLC now owns 111 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 99 shares during the period. GAMMA Investing LLC boosted its position in shares of Madrigal Pharmaceuticals by 131.4% during the 1st quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 67 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Madrigal Pharmaceuticals by 38.9% in the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 44 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $70,000. Institutional investors and hedge funds own 98.50% of the company's stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.